Background: Intraoperative radiotherapy (IORT) has advantages over external beam radiation therapy (EBRT). Few studies have described side effects associated with its addition. We evaluated our institution's experience with abdominopelvic IORT to assess safety by postoperative complication rates. 
several mechanisms are involved which lead to direct damage to cellular DNA and the formation of free radicals, resulting in apoptosis of tumor cells. However, these effects also damage adjacent normal cells and tissue, leading to the potential toxicities that can be seen with radiation therapy. 2, 4 External beam radiotherapy (EBRT) is used to deliver fractionated doses, allowing for the highest dose to tumor cells while minimizing the amount of radiation exposure to adjacent normal tissue.
Preoperative EBRT benefits from an undisrupted vascular supply, increasing oxygenation and allowing for the formation of toxic free radicals. Adjacent normal structures are also displaced by the tumor, which has not yet been resected. 1, 2 Preoperative EBRT may also alter the ability of tumor cells that become disrupted at the time of surgical resection to implant and cause dissemination or recurrence. Postoperative EBRT, on the other hand, can target residual tumor cells in the resection bed, as opposed to preoperatively when a much larger tumor burden is being treated. However, the radiation oncologist must now contend with adjacent bowel and normal tissue which obstruct the path of radiation to the tumor bed and contribute to significant toxicity as a result. 1, 2 Intraoperative radiotherapy (IORT) offers several advantages in that it is able to directly target microscopic or gross residual disease, or close tumor margins, immediately following surgical resection. 2, 3, 5 However, unlike postoperative EBRT, adjacent organs are able to be displaced, protected, and shielded so that the maximum dose can be delivered to at-risk areas identified during resection with lower radiation toxicity than that given by an increased dose of EBRT alone. 2, 3, 5 In fact, because of this ability to directly administer radiotherapy, the high single-treatment dose given during IORT is equivalent to 2.5 times that dose by EBRT. 5, 6 For example, a typical dose given during IORT, 15 Gy, is equivalent to about 37.5 Gy by EBRT, effectively nearly doubling a typical cumulative dose given in pre-or postoperative EBRT.
This study reviews our institution's experience in initiation and incorporation of IORT into the treatment paradigm of locally advanced or recurrent intra-abdominal malignancies. We assess the safety of IORT with regards to postoperative acute and long-term surgical complications, and demonstrate that surgical complication rates with IORT are acceptable and non-inferior to historical previously published rates in comparable advanced malignancies.
| MATERIALS AND METHODS

| Study population
All patients receiving IORT to the abdomen, pelvis, and retroperitoneum were included in this study beginning from the initiation of the IORT program at Johns Hopkins Hospital in November 2006 until May 2014.
Abdominopelvic IORT included retroperitoneal IORT. Patients were discussed and determined to be appropriate candidates for IORT in a multidisciplinary collaboration which included pathology, surgical oncology, medical oncology, and radiation oncology. All patients were discussed in their respective disease-based multidisciplinary conferences (MDC) such as sarcoma MDC, colorectal MDC, etc. Patients selected for intraoperative radiation therapy were patients in whom curative intent resection was being attempted. IORT in these cases was determined to potentially improve margin-negative resection and optimize locoregional control. The medical records of all patients were reviewed for patient characteristics, comorbidities, indications, radiotherapy administration details, and postoperative complications.
Degree of comorbidity was assessed using the Charlson Comorbidity Index (CCI). It is important to note that CCI gives a score of 2 for nonmetastatic solid tumors and 6 for metastatic tumors, so all patients in this study had a minimum CCI score of either 2 or 6 before factoring in other comorbidities. All forms or variations of EBRT, including intensity modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), and 3-D conformational radiotherapy (3D-CRT), were classified together as EBRT.
| IORT technique
IORT details were obtained from radiation oncology procedure notes in the medical record. Our institution's technique, known as high dose rate brachytherapy (HDR-IORT) has been previously described in detail. 5 This technique combines IORT with brachytherapy, a form of radiation in which a local radiation source is implanted inside or next to the area requiring treatment. Briefly, high-dose-rate brachytherapy catheters are threaded through flexible silicone applicators known as
Freiburg flaps that can be cut and shaped to accurately resemble the target area being irradiated. The room is then cleared and radiation therapy administered. Freiburg flaps offer an advantage over the comparatively rigid cone applicators used in intraoperative electron beam radiotherapy (IOERT) and IORT with low energy photons. 5 The flaps also deliver a more concentrated dose at the surface of the target area compared to IOERT, which delivers more homogeneous doses throughout the tissue depth. 3, 7 Number of fields, dosages, treatment area, and treatment depths were determined by the treating radiation oncologist on an individual basis. Most patients received either pre-or postoperative EBRT as well, and this is detailed in the results.
| Complications
Perioperative complications were classified according to the ClavienDindo classification system for postoperative surgical complications. 
| Statistical analysis
Tests for interactions between different variables were performed using the chi-squared test. P-value less than 0.05 was considered statistically significant. Statistical analyses were performed using the STATA 10.0 statistical software. A smaller number of colorectal cancers receiving IORT were primary tumors (16%), and these were all T4 rectal cancers invading adjacent structures which were predicted to have close margins on resection.
The most common location for tumors was in the pelvis (53%)
followed by the retroperitoneum (33%) and intraperitoneal abdomen (14%). A total of 64% of sarcomas were in the retroperitoneum, and 87% of all retroperitoneal tumors were sarcomas (P < 0.001).
Conversely, 71% of all colorectal cancers were in the pelvis, and colorectal cancer made up 53% of all pelvic tumors (P < 0.001). Nearly all patients (96%) had either an R0 or R1 resection (R0: 51%, R1: 45%).
This is a high rate of R0 resection and the final resection margin would not be known until postoperatively, but these patients also had locally invasive disease and were determined to be at risk for positive margins after resection during preoperative multidisciplinary discussion.
Additionally, the majority of these R0 resections also received preoperative EBRT (72%), which may have allowed for higher rates of microscopically negative margins. In terms of wound closure, 39%
of patients had a tissue flap without mesh, 7% had a tissue flap with mesh, and 54% had no flap.
| Radiation therapy characteristics
The majority of patients (80%) underwent external beam radiation therapy (EBRT) either pre-or postoperatively (Table 2) The technique of delivering radiation to the surface versus deeper into the tissue is dependent on the amount of time the brachytherapy catheters remain in the dwell position. To deliver radiation to 5 mm depth below the surface, the radiation source remains in the dwell position for a longer period of time than if radiation is delivered to the surface alone. This also results in a higher surface dose and can potentially result in increased complications and/or decreased healing.
On statistical analysis, there were no significant interactions between type of cancer and location of tumor with relation to treatment depth, number of fields, or dose administered.
| Complications
Complication rates are outlined in Table 3 . There were no deaths in the first 30 days after surgery and IORT. Specific complications for each category of wounds are outlined in Table 4 . Abscesses were the most common type of wound complication (16 patients, 37% of all wound complications), followed by surgical site infection causing dehiscence/opened by the surgeon to drain (14 patients, 33% of wound complications), and delayed/nonhealing wound (14 patients, 33% of wound complications). One patient experienced necrotizing fasciitis resulting in evisceration and required re-operation. The most common gastrointestinal complication was small bowel obstruction or ileus which did not resolve without intervention (ie, nasogastric decompression or surgical intervention;
15 patients, 54% of GI complications). Seven patients developed enteric fistulas (enterocutaneous, entero-enteric, etc; 25% of GI complications), and five patients (18% of GI complications) had GI tract inflammation (three enteritis, one gastritis, one esophagitis + duodenal ulcer). The most common genitourinary complication was obstruction resulting in hydroureter/hydronephrosis (six patients, 35% of GU complications) followed by prolonged inability to void (three patients, 18% of GU complications). Neuropathy consisted of neuropathic pain in eight patients (62% of neurologic complications) and weakness/ numbness/paresthesia in five patients (39% of neuro complications). It is difficult to determine the complications that are due exclusively to surgery or IORT, and it is likely that they are due to a combination of the two factors. However, certain complications are likely related more closely to surgical factors, such as abscesses, surgical site infections, wound dehiscence, and small bowel obstruction/ileus.
Others are more likely a toxicity of IORT treatment including delayed/ non-healing chronic wounds, GI tract inflammation, and neuropathy.
Several factors contributed to increased rates of specific complication types. In comparing the two most frequent cancer diagnoses (sarcoma and colorectal cancer), there was a greater number of genitourinary complications in colorectal cancer than in sarcomas, and this difference was statistically significant (8% sarcoma vs 27% colorectal cancer, P = 0.015; Table 5 ). Additionally, a tumor located in the pelvis was also more likely to result in genitourinary complications compared to any other location (25% pelvis vs 13% abdomen and 0% retroperitoneum, P = 0.003; Table 5 ). Flap closure of the wound, with or without mesh, increased the rate of wound complications compared to closure without a flap (50% flap vs 32% no flap, P = 0.053; Table 5 ).
No other interactions between diagnoses or location were Relapse rates for rectal cancer have historically been as high as 50% 12 with improved rates recently due to total mesorectal excision (TME) and incorporation of EBRT. [13] [14] [15] However, in recurrent and locally advanced rectal cancer, obtaining margin negative resection often requires extensive surgery including abdominoperineal resection (APR) and pelvic exenteration along with radiation, and IORT is able to increase radiation to at risk areas beyond doses given by EBRT alone while attempting to minimize further GI toxicity. Outcomes reported from preoperative EBRT combined with IORT in locally advanced primary colorectal cancer have demonstrated local control rates as high as 95%, disease-specific survival rates of 63%, and overall 5 year survival rates of 46%. 1, 16, 17 Benefits in recurrence and survival have also been reported in locally recurrent colorectal cancer.
18-21
Recent systematic reviews and meta-analyses of IORT in colorectal cancer have concluded that data thus, far points to improvements in local control rates and, to a lesser extent, overall survival. 22, 23 The main outcome evaluating the determination of success in IORT thus, far is the presence or absence of locoregional recurrence. However, a key factor for locoregional recurrence with or without IORT remains resection margins, and some studies have questioned the utility of implementing IORT in the context of R0 resections. IORT, but no difference in survival. 28 More recent studies using preoperative EBRT with and without IORT have shown favorable local control rates with this combination. [29] [30] [31] Along with decreases in local recurrence rates, however, some studies in colorectal cancer have shown increases in postoperative morbidity and complication rates with IORT, especially in terms of wound complications, hemorrhagic complications, and genitourinary complications. One meta-analysis in colorectal cancer demonstrated that IORT did not increase risk of anastomotic, urologic, or overall complications compared to surgery alone. 22 However, pooled analysis did show a borderline increased risk of wound complications (OR 1.86, 95% CI 1.03-3.38). 22 A systematic review of IORT in colorectal cancer found the incidence of reported severe complications with IORT to vary between 30% and 40%, and the most common types of complications to be gastrointestinal, dermatologic (primarily wound), and infections related to surgery. These complication rates are also not inferior to what has been reported for surgery alone in comparable patient cohorts. Surgery for locally recurrent rectal cancer, which often requires en-bloc multi-visceral resections, has postoperative morbidity rates between 30% and 60%. 32 One study also reported a major complication rate of 27% for extended radical resection in recurrent rectal cancer. 33 Similarly, large retroperitoneal sarcomas requiring extensive multivisceral resection also have significant perioperative morbidity rates independent of the incorporation of IORT. One study in primary retroperitoneal sarcomas evaluated outcomes of compartmental resection, which is an aggressive approach that treats the retroperitoneum like an extremity compartment and attempts to achieve wide margins by resecting organs adjacent to the sarcoma regardless of whether they are involved by tumor. 34 They reported a complication rate of 16%, although half of these required reoperation. Additionally, there were 13 perioperative deaths (4%) and 3 intraoperative deaths. 34 It is important to note that our patients were chosen for IORT from patients evaluated in multidisciplinary conferences which allow for input from experts of all disciplines involved. These collaborations are crucial and necessary. Without this multidisciplinary approach, one would expect higher complication rates, especially in smaller centers or centers that do not have similar volume or experience in administering IORT.
There are several limitations to our study. First, this study is a retrospective chart review and may suffer from incomplete or missing documentation in the chart. Second, we described the perioperative outcomes, complication rates, and effects on types of complications of variables related to IORT therapy. However, we do not have a comparable cohort of patients during this time period which did not receive IORT therapy to compare the effects of IORT to surgery ± EBRT alone. All patients that were determined to be candidates for and potentially benefit from IORT during this time period were evaluated by radiation oncology and received IORT if appropriate. Our paper combined various disparate cancer diagnoses, although the most common were sarcomas and colorectal cancers. These patients were self-selected through their clinical workup and diagnosis as patients identified as suffering from locally aggressive cancers which would benefit most from IORT. Additionally, we are not offering a direct comparison between a treatment group of IORT + surgery and a control group of surgery alone. This would require a controlled trial or case control study directly comparing these two treatment arms, and is beyond the scope of this current paper. By presenting previously published data on complication rates in resection of locally advanced/ recurrent rectal cancer and intra-abdominal sarcoma, our intention was simply to place the complication rates presented in our study within the appropriate context of what is considered an acceptable postoperative morbidity for this patient cohort. Lastly, we have not discussed the effects on local control, disease free survival, and overall survival in this paper, however, this data are still being collected and assessed, and will be addressed in the future.
| CONCLUSIONS
We have described the patient and treatment characteristics of IORT patients treated at Johns Hopkins Hospital over the 8 year period beginning in November 2006. Our study is one of the largest series on IORT that has been published to date. Our most common diagnoses were sarcoma, followed by colorectal cancer. The rate of high grade complications (at least Grades III or IV) was 34%, and the most common complication type was | 889
